title: Lack of an antagonist to reverse the action of dabigatran.
authors: O M P
authors: OM
authors: Jolobe
mesh_terms: D000925:Anticoagulants / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000494:pharmacology; D000069604:Dabigatran; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D009025:Morpholines / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000037:antagonists & inhibitors; D014859:Warfarin / Q000037:antagonists & inhibitors; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D001779:Blood Coagulation Factors; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; C025667:prothrombin complex concentrates; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran